Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OmniAb, Inc. (NASDAQ: OABI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to its official public record. OmniAb is a technology company that licenses discovery research platforms for antibody and peptide therapeutics, and its filings offer detail on how this business is structured and financed.
OmniAb’s current reports on Form 8-K include announcements of quarterly and year-to-date financial results, where the company breaks out revenue from license and milestone agreements, services, xPloration® instrument sales and related consumables, and royalties. These filings also discuss research and development and general and administrative expenses, other operating income, and net loss figures, giving context to the economics of its technology licensing and discovery services model.
Other 8-K filings describe material events such as securities purchase agreements for private placements of common stock. In these documents, OmniAb outlines the number of shares sold, purchase prices, intended use of proceeds for working capital and general corporate purposes, and related registration rights. Filings also confirm that OmniAb’s common stock is listed on The Nasdaq Global Market under the symbol OABI, with warrants listed on The Nasdaq Capital Market under OABIW, and that the company qualifies as an emerging growth company.
Shareholder-focused filings, including reports on annual meetings, provide voting results for director elections and ratification of the independent registered public accounting firm. Together, these SEC documents help investors analyze governance, capital structure, financing transactions, and the financial performance of OmniAb’s antibody discovery technology business. Stock Titan enhances this information with AI-powered summaries that explain key points from forms such as 10-K, 10-Q, 8-K, and ownership reports, helping readers quickly understand the implications of each filing.
OmniAb, Inc. (OABI) – Form 4 insider activity dated 06/17/2025
Director John L. Higgins reported multiple equity transactions. He converted 20,000 previously granted RSUs (transaction code M), receiving an equal number of common shares at no cash cost and lifting his directly held stake to 2,851,887 shares. No shares were sold.
On the same day, the board granted Higgins a new equity package comprising 20,000 RSUs and 40,000 stock options with a $1.70 exercise price expiring 06/17/2035. Both awards vest in full on the earlier of the next annual shareholder meeting or 12 months from grant, aligning with the company’s typical director compensation schedule.
Post-transactions, Higgins’ derivative exposure consists of 33,172 unvested RSUs and 40,000 unexercised options. The filing signals continued long-term alignment as the insider’s net ownership increased and no dispositions were made. The incremental dilution from the new awards is de minimis relative to OmniAb’s outstanding share count and does not alter the firm’s capital structure.
Form 4 filing for OmniAb, Inc. (OABI) dated 18-Jun-2025 discloses equity transactions by director Carolyn R. Bertozzi on 17-Jun-2025.
- Common stock: 20,000 shares were acquired upon vesting of previously granted restricted stock units (RSUs). Post-transaction direct ownership stands at 75,539 shares.
- New equity grants: (i) 20,000 RSUs, each convertible into one common share, and (ii) a stock option for 40,000 shares with a $1.70 exercise price and 17-Jun-2035 expiration. All new awards vest in full on the earlier of the next annual shareholder meeting or the first anniversary of the 17-Jun-2025 grant date.
- No dispositions of shares occurred; all reported transactions increase or maintain the insider’s exposure to OmniAb’s equity.
These routine director equity awards and vesting events align incentives with shareholders and do not, by themselves, alter OmniAb’s fundamentals. The filing satisfies Section 16 reporting obligations and contains no indications of sales, pledges, or derivative hedging.